YOLFTbeta
DK Life Science Co., Ltd.

DK Life Science Co., Ltd.

303810 · KQ · Healthcare / Medical Instruments & Supplies

1,754.00KRW-31.00 (-1.74%)

Price History

Full chart

Market Stats

Previous Close1,785.00
Open1,798.00
Day Range1,753.00 – 1,823.00
52-Week Range2,155.00 – 4,160.00
Volume176.64K
Market Cap89.88B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
50-Day Avg2,411.70
200-Day Avg3,040.35

About

DK Life Science Co., Ltd., a pharmaceutical company, develops and sells diagnostic medicines and medical devices in South Korea and internationally. It offers active pharmaceutical ingredients (API), injections, blood glucose self-monitoring device, Mobile CT equipment, and ultrasonic instruments. The company also offers catheters, MRI, CT scanner, ultrasound, mobile CT scanner, and X-ray equipment, as well as mammography image analysis assistance software. DK Life Science Co., Ltd. was founded in 2017 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMr. Jae Won Park
  • HeadquartersTeheran-ro 108-gil 7, Seoul, South Korea, Korea
  • Websitehttps://www.dkls.co.kr

Leadership

  • Mr. Jae Won ParkCEO & Representative Director · b. 1965
  • Mr. Ki-Cheol KimDirector of the Finance Department · b. 1978
  • Mr. ChangHyun KimMarketing Director · b. 1977
  • Mr. YeongSeon KimSenior Managing Director · b. 1969
  • Mr. Heesung YangSenior Managing Director · b. 1963
  • Ms. SooJin KwonVP & Inside Director · b. 1968

Financials

Income Statement

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Revenue107.23B120.16B131.82B130.34B
Growth (%)-+12.05%+9.70%-1.12%
Cost of Revenue85.04B94.90B103.23B97.34B
Gross Profit22.19B25.26B28.59B33.00B
Gross Margin20.70%21.02%21.69%25.32%
Operating Expense15.96B16.73B16.67B19.95B
Operating Income6.23B8.53B11.92B13.05B
Operating Margin5.81%7.10%9.04%10.01%
EBITDA11.36B13.11B18.52B21.02B
EBITDA Margin10.60%10.91%14.05%16.12%
Net Income4.24B4.17B2.24B8.66B
Net Income Margin3.95%3.47%1.70%6.64%
R&D1.01B1.14B1.47B1.92B
R&D as % of Total Revenue0.95%0.95%1.11%1.47%
Interest Expense3.62B4.99B7.99B3.78B
Interest Expense % of Total Revenue3.38%4.16%6.06%2.90%

Balance Sheet

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Assets164.43B179.13B191.66B217.63B
Total Liabilities99.30B110.42B86.43B86.26B
Total Equity65.13B68.70B105.22B131.37B
Cash1.38B3.42B2.40B1.96B
Net Debt39.72B43.66B42.40B34.74B

Cash Flow

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.92B-4.61B11.54B433.65M
Capital Expenditure17.38B4.79B5.08B5.69B
Free Cash Flow-20.30B-9.40B6.45B-5.26B
FCF to OCF696.06%203.97%55.95%-1212.29%

Earnings

Report DateMar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------
EPS Actual70.3489.1675.3939.8072.09-27.76
Surprise------
Timing------

Key Statistics & Ratios

Market Cap89.88B
Enterprise Value119.03B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.76
Price / Book0.67
Revenue (TTM)117.75B
Gross Profit (TTM)29.78B
EBITDA16.77B
Profit Margin4.23%
Operating Margin0.09%
Return on Equity3.82%
Return on Assets3.01%
Shares Outstanding31.98M
Shares Float11.99M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Aug 7, 20252:1